secwatch.observer — SEC 8-K summary
======================================

Issuer:     X4 Pharmaceuticals, Inc (XFOR)
CIK:        0001501697
Form:       8-K
Filed at:   2023-05-16T23:59:59+00:00
Accession:  0001628280-23-018424
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 1.01, 3.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

X4 Pharma announces $65M PIPE and positive Phase 3 mavorixafor data in WHIM syndrome
--------------------------------------------------------------------------------

- 42.8M shares/pre-funded warrants priced at $1.52, raising $65M gross; expected close May 18, 2023.
- Phase 3 4WHIM trial: mavorixafor reduced annualized infection rate by ~60% vs placebo (p<0.01).
- Severe (Grade≥3) infections cut by 75%; mean infection duration reduced >70% (2 weeks vs 7 weeks on placebo).
- NDA submission for mavorixafor in WHIM syndrome on track for early 2H 2023 after pre-NDA meeting with FDA.
- Cash runway extended into Q4 2024, excluding potential priority review voucher proceeds.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1501697/000162828023018424/0001628280-23-018424-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1501697/000162828023018424/xfor-20230515.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-018424

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer